Search Results
2 results
| To filter these results use the options in the right hand panel | |
|---|---|
|
This issue of Vital Signs, released on December 6, 2010, provides a strategic overview of key issues and trends relating to next-generation sequencing. Additionally, a company spotlight is provided for GenturaDx, a company who has an exclusive license to more than 100 patents for assays, which should allow the company to develop an incredibly broad and robust menu of tests. Reimbursement
|
|
| Published: 6 Dec 2010 | Market Research |
|
diagnostic Californian Company GenturaDx. The deal will be closing at $50 million cash along with additional payments depending... diagnostic testing system that integrates its MultiCode-RTx chemistry with GenturaDx’s system, allowing substantial spike in multiple
|
|
| Published: 20 Jul 2012 | Technical Insights Alerts |
- page 1 of 1
Help Desk
For more information and general enquiries, contact Frost & Sullivan near you.
Select a location near you..